Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis
18 avr. 2024 07h00 HE
|
Chemomab Therapeutics
Peer-reviewed patient study validates Chemomab's CCL24 as a novel target linked to greater disease severity and higher mortality in systemic sclerosis
BioSenic présente des données précliniques concluantes sur son médicament ATO pour le contrôle des principaux symptômes au Congrès mondial 2024 sur la sclérose systémique
20 mars 2024 02h00 HE
|
BioSenic
COMMUNIQUE DE PRESSE Des données précliniques dans un modèle de souris transgénique montrent des effets bénéfiques sur divers symptômes cliniques analogues à ceux observés dans la sclérose...
BioSenic presents successful preclinical data on its ATO medication for controlling key symptoms at the 2024 Systemic Sclerosis World Congress
20 mars 2024 02h00 HE
|
BioSenic
PRESS RELEASE Preclinical data in a transgenic mouse model shows beneficial effects on various clinical symptoms analogous to those observed in human systemic sclerosis.Findings may further support...
Global Scleroderma Market Forecasts Promising Growth with Latest Industry Trends by 2027
30 janv. 2024 20h25 HE
|
Research and Markets
Dublin, Jan. 30, 2024 (GLOBE NEWSWIRE) -- The "Global Scleroderma Market Report 2023" report has been added to ResearchAndMarkets.com's offering. The global scleroderma market is poised for...
APIE Therapeutics Provides Evidence that Activating the Apelinergic System can Repair and Regenerate Lung Tissue Damaged by Pulmonary Fibrosis
30 août 2022 08h00 HE
|
APIE Therapeutics
CARY, NC , Aug. 30, 2022 (GLOBE NEWSWIRE) -- APIE Therapeutics (APIE Tx), a preclinical pharmaceutical company pioneering novel and proprietary drugs to activate the apelin receptor (APJ), presented...
APIE Therapeutics Presented Preclinical Findings Supporting Activation of the Apelin Receptor as a Therapeutic Approach for Systemic Sclerosis
02 août 2022 10h15 HE
|
APIE Therapeutics
Cary, NC, Aug. 02, 2022 (GLOBE NEWSWIRE) -- APIE Therapeutics, a preclinical pharmaceutical company pioneering novel and proprietary anti-fibrotic drugs that target the apelin receptor (APJ),...
APIE Therapeutics Augments Leadership Team with Addition of Chief Business Officer and Chief Medical Officer
12 janv. 2022 07h30 HE
|
APIE Therapeutics
Cary, NC, Jan. 12, 2022 (GLOBE NEWSWIRE) -- APIE Therapeutics, a preclinical biopharma company pioneering microvasculature endothelium drug development by targeting the apelin receptor (APJ),...
Corbus Pharmaceuticals Presents Additional Data from RESOLVE-1 Study in Systemic Sclerosis
09 nov. 2020 08h05 HE
|
Corbus Pharmaceuticals Holdings, Inc.
Topline data remain as previously reportedPost-hoc analyses showed lenabasum treatment was associated with a benefit in lung function (forced vital capacity) in subjects on established background...
Corbus Pharmaceuticals Announces Three Lenabasum Abstracts to be Presented at ACR Convergence 2020
21 oct. 2020 08h05 HE
|
Corbus Pharmaceuticals Holdings, Inc.
Preliminary baseline subject demographics and disease characteristics in a Phase 3 clinical trial of the safety and efficacy of lenabasum in dermatomyositis (DETERMINE)Cannabinoid receptor type 2...
Corbus Pharmaceuticals Announces Topline Results from RESOLVE-1 Phase 3 Study of Lenabasum for Treatment of Systemic Sclerosis
08 sept. 2020 07h05 HE
|
Corbus Pharmaceuticals Holdings, Inc.
Topline data showed no significant differences in the primary and secondary endpoints when comparing lenabasum to placebo, both added to background drug therapyUnprecedented improvement was observed...